Medicare Bundled Payment Policy on Anemia Care, Major Adverse Cardiovascular Events, and Mortality among Adults Undergoing Hemodialysis

CONCLUSIONS: The Medicare reimbursement policy and Food and Drug Administration-recommended erythropoietin-stimulating agent dosing changes were associated with lower erythropoietin-stimulating agent use and lower hemoglobin levels. These changes in anemia care were associated with lower risks of major adverse cardiovascular event, stroke, mortality, and heart failure but higher risk of acute myocardial infarction among adults receiving hemodialysis.PMID:35589388 | DOI:10.2215/CJN.14361121

Source: Clinical Journal of the American Society of Nephrology : CJASN - May 19, 2022 Category: Urology & Nephrology Authors: Haesuk Park Raj Desai Xinyue Liu Steven M Smith Juan Hincapie-Castillo Linda Henry Amie Goodin Saraswathi Gopal Carl J Pepine Raj Mohandas Source Type: research